Literature DB >> 2874502

Biochemical and pharmacological effects of fluperlapine on noradrenaline and acetylcholine systems in some rodent, bovine and crustacean preparations.

C Rüdeberg, S Urwyler, C Schulthess, P L Herrling.   

Abstract

Fluperlapine was compared with clozapine, chlorpromazine, haloperidol and imipramine regarding its effects on some cholinergic and noradrenergic animal systems. Fluperlapine and clozapine showed the most pronounced anticholinergic effects. Fluperlapine was equipotent with clozapine in displacing [3H]-QNB from muscarinic receptors of the calf cerebral cortex (IC50 about 15 nM). In the mydriasis test in the mouse and in the crayfish hindgut bioassay the differences between fluperlapine and clozapine were small. Like the other antischizophrenic drugs tested, fluperlapine displayed a marked affinity for alpha 1-adrenoceptors (calf cerebral cortex: IC50 about 10 nM) but a negligible affinity for alpha 2-adrenoceptors in the same tissue. Only clozapine showed a weak affinity for the latter receptor type. Fluperlapine was as effective as imipramine in antagonizing tetrabenazine-induced ptosis in the rat, the anti-ptotic effect remaining constant after up to ten daily drug administrations. Still, imipramine was stronger than fluperlapine as an inhibitor of the accumulation of [3H]-noradrenaline ([3H]-NA) in rat cerebral cortex slices. Fluperlapine's effects on the spontaneous and the electrically-induced release of [3H]-NA from rat cerebral cortex slices, with and without protriptyline, showed it to be an inhibitor of the reuptake of NA. The results indicate that the pharmacological profile of fluperlapine is similar to that of clozapine, with additional antidepressant properties.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874502     DOI: 10.1007/bf00500087

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  38 in total

1.  A new test preparation for bio-assay of factor I and gamma-aminobutyric acid.

Authors:  E FLOREY
Journal:  J Physiol       Date:  1961-04       Impact factor: 5.182

2.  Tricyclic antidepressants: therapeutic properties and affinity for alpha-noradrenergic receptor binding sites in the brain.

Authors:  D C U'Prichard; D A Greenberg; P P Sheehan; S H Snyder
Journal:  Science       Date:  1978-01-13       Impact factor: 47.728

3.  Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain.

Authors:  S J Peroutka; D C U'Prichard; D A Greenberg; S H Snyder
Journal:  Neuropharmacology       Date:  1977-09       Impact factor: 5.250

4.  Trazodone, a new nontricyclic antidepressant without anticholinergic activity.

Authors:  D P Taylor; D K Hyslop; L A Riblet
Journal:  Biochem Pharmacol       Date:  1980-08-01       Impact factor: 5.858

5.  Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors.

Authors:  P Greengrass; R Bremner
Journal:  Eur J Pharmacol       Date:  1979-05-01       Impact factor: 4.432

6.  Complex action of antidepressant treatment on central adrenergic system: possible relevance to clinical effects.

Authors:  J Vetulani
Journal:  Pharmacopsychiatry       Date:  1984-01       Impact factor: 5.788

7.  Pharmacology of fluperlapine compared with clozapine.

Authors:  E Eichenberger
Journal:  Arzneimittelforschung       Date:  1984

8.  Fluperlapine in tardive dyskinesia and parkinsonism.

Authors:  S Korsgaard; U Noring; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Attenuation by chronic imipramine treatment of [3H]clonidine binding to cortical membranes and of clonidine-induced hypothermia: the influence of central chemosympathectomy.

Authors:  A Pilc; J Vetulani
Journal:  Brain Res       Date:  1982-04-29       Impact factor: 3.252

10.  Effects of alpha-adrenoceptor agonists and antagonists and of antidepressant drugs on pre- and postsynaptic alpha-adrenoceptors.

Authors:  J Brown; J C Doxey; S Handley
Journal:  Eur J Pharmacol       Date:  1980-10-03       Impact factor: 4.432

View more
  3 in total

1.  SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity.

Authors:  R Markstein; P Gull; C Rüdeberg; S Urwyler; A L Jaton; K McAllister; A K Dixon; D Hoyer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Telescoped synthesis of C3-functionalized (E)-arylamidines using Ugi-Mumm and regiospecific quinazolinone rearrangements.

Authors:  Victor A Jaffett; Alok Nerurkar; Xufeng Cao; Ilia A Guzei; Jennifer E Golden
Journal:  Org Biomol Chem       Date:  2019-03-20       Impact factor: 3.876

3.  SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors.

Authors:  R Markstein; P Gull; C Rüdeberg; S Urwyler; A L Jaton; H O Kalkman; A K Dixon; D Hoyer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.